Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Prostetica
Trento, Trentino-Alto Adige, Italy
- Ownership
- Private
- Development stage
- Other
01
Overview
Prostetica is an Italian biotechnology company focused on the development of innovative therapies for the treatment of advanced prostate cancer. A spin-off from the University of Trento and the University of Bologna, the company leverages research into the role of the tumor microenvironment and senescence in cancer progression. Its primary focus is the development of small molecule inhibitors targeting CXCR2 to overcome therapy resistance in castration-resistant prostate cancer. By modulating the immune response within the tumor, Prostetica aims to restore sensitivity to standard hormonal treatments and improve patient outcomes.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Prostetica.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prostetica.